Zydus Lifesciences LTD

Zydus Lifesciences Ltd (ZYDUSLIFE) is a large-cap Healthcare company valued at ₹1.12 lakh crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Zydus Lifesciences Ltd last traded at ₹1,123, modestly down 1.51% on the day.

Recent developments

On 2026-09-29, the company's stock was part of a broader market downturn, with the Nifty 50 declining 360.25 points. On 2026-09-26, the company received a positive regulatory update as its New Jersey facility cleared a USFDA inspection with no observations. On 2026-08-21, the company's shares rose on news of a USFDA approval for Ascorbic Aid Injection.

Financial performance

The company's business is improving, with annual revenue rising 16.8% and annual net profit growing 9.6%. However, the latest quarter shows a sharp decline in net profit, falling 34.9% compared to the same quarter a year earlier, while revenue rose 22.0%.

Valuation multiples

The stock trades at 22.4 times earnings, a discount to the Healthcare median of 32.0, 4.11 times book value. It yields 0.1%.

Things to watch

The company's net profit margin has narrowed by 1.2 percentage points to 18.9%. The stock is 9.3% below its 52-week high. The latest quarter's net profit fell 34.9% compared to the same quarter a year earlier.

Where it stands

Zydus Lifesciences has seen strong revenue growth over the past three years, with a 16.4% CAGR, but its latest quarter's net profit dropped sharply. The stock is trading below its 52-week high, and the net profit margin has declined. The most significant movement is the 34.9% drop in net profit for the latest quarter.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.